Information Provided By:
Fly News Breaks for February 12, 2018
SRPT
Feb 12, 2018 | 07:15 EDT
H.C. Wainwright analyst Debjit Chattopadhyay believes the temporary halt to recruitment in the U.K. in the ongoing global Essence pivotal program is unlikely to have any readthrough into the ongoing discussions with the FDA on a conditional approval for golodirsen. The selloff in Sarepta's stock over the past six trading days is "potentially overdone," Chattopadhyay tells investors in a research note. The analyst remains a buyer of Sarepta with a Buy rating on the shares and $75 price target.
News For SRPT From the Last 2 Days
There are no results for your query SRPT